Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-117.
American Society for Gastrointestinal Endoscopy. Management of antithrombotic agents for endoscopy procedures. Gastrointestinal Endoscopy. 2009;70:1060-1071.
Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations). A report from the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:1916-1926.
Beinart R, Boyko V, Schwammenthal E, et al. Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol. 2004;44:327-334.
Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92:835-841.
Borzecki AM, Bridgers DK, Liebschutz JM, et al. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc. 2008;100:237-245.
BRIDGE Study Investigators. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation. 2012;125:e496-e498.
Cairns JA, Connolly S, McMurtry, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Canadian J Cardiol. 2011;27:74-90.
Calvo N, Brugada J, Sitges M, Mont L. Atrial fibrillation and atrial flutter in athletes. Br J Sports Med 2012;46(Suppl I):i37-i43.
Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guideline for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-2747.
Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008;51:1-11.
Chan PS, Maddox TM, Tang F, et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE Program). Am J Cardiol. 2011;108:1136-1140.
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
Connolly SJ, Ezekowtiz, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078.
Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004;57:798-806.
Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Am Heart J. 2005;149:650-656.
Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e326S-e350S.
Drugs.com. Warfarin drug interactions. http://www.drugs.com/drug-interactions/warfarin.html. Accessed September 11, 2013.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885-1889.
Eliquis (apixaban) full prescribing information. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed September 11, 2013.
Ezekowitz M, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naïve and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-2253. Circulation. 2010;122:2246-2253.
Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469-473.
Fisher M, Loscalzo J. The perils of combination antithrombotic therapy and potential resolutions. Circulation. 2011;123:232-235.
Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e269-e367.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
Garcia DA, Granger CB. Anticoagulation, novel agents, and procedures. Can we pardon the interruption? Circulation. 2012;126:255-257.
Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, et al. Comparison between CHADS2 and CHA2DS2-VASc score in stroke cohort with atrial fibrillation. Eur J Neurol. 2013;20:623-628.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
Guyatt GH,, Akl EA, Crowther M, et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidenced-based clinical practice guidelines. Chest. 2012;141(2 suppl):7S-47S.
Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141-S145.
Lin H, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. Stroke. 1996;27:1760-1764.
Lip GYH, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-2738.
Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2011;57:173-180.
Lip GYH. Can we predict stroke in atrial fibrillation. Clin Cardiol. 2012;35(suppl 1):21-27.
Lip GYH, Douketis JD. Management of anticoagulation before and after elective surgery. 2013. UpToDate website. www.uptodate.com/contents/management-of-anticoagulation-before-and-after-elective-surgery. Accessed September 1, 2013.
Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123:484-488.
Ma X, Zhang X, Guo W. Factors to predict recurrence of atrial fibrillation in patients with hypertension. Clin Cardiol. 2009;32:264-268.
Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29:171-181.
Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med. 2003;163:1580-1586.
National Heart, Lung, and Blood Institute of the National Institutes of Health. BRIDGE study overview. April 2010. https://bridge.dcri.duke.edu/Study%20Overview%2013Apr2010.pdf. Accessed September 5, 2013.
Nieuwlaat R, Barker L, Kim YK, et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res. 2010;125:128-131.
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638-645.
Ogilvie Im, Welner SA, Cowell W, Lip GY. Ischemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb Haemost. 2011;106:34-44.
Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106:739-749.
Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost. 2012;107:1172-1179.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.
Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation Study. Chest. 2012;141:339-347.
Pradaxa® (dabigatran) full prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed September 11, 2013.
Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure. The epidemiology, practice, outcomes, and costs of heart failure (EPOCH) study. J Am Coll Cardiol. 2004;43:429-435.
Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954-2962.
Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2004;17:644-648.
University of Utah Health Care. Thrombosis Service. http://healthcare.utah.edu/thrombosis/patients/warfarin_esp/Common%20drug%20interactions%20with%20warfarin.pdf. June 25, 2010. Accessed September 1, 2013.
Vavra KA, Lutz MF, Smythe MA. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother. 2010;44:718-726.
Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64:956-967.
Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-7.
Wheeler R, Masani ND. The role of echocardiography in the management of atrial fibrillation. Eur J Echocardiogr. 2011;12:i33-i38.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
Xarelto® rivaroxaban tablets full prescribing information. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100. Accessed September 11, 2013.